National Research/$NRC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About National Research

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.

Ticker

$NRC
Primary listing

Industry

Health Care Providers & Services

Employees

368

ISIN

US6373722023

NRC Metrics

BasicAdvanced
$384M
16.51
$1.02
0.36
$0.48
2.85%

Bulls say / Bears say

NRC Health's recent partnerships with healthcare providers like UofL Health and Renown Health aim to enhance patient and employee experiences, potentially leading to increased client retention and revenue growth. (businesswire.com, businesswire.com)
The appointment of Trent Green as CEO in March 2025 brings experienced leadership, which may drive strategic initiatives and operational improvements. (businesswire.com)
NRC Health's recognition as the #1 Best in KLAS for Healthcare Experience Management in February 2025 enhances its reputation, potentially attracting new clients and strengthening market position. (businesswire.com)
NRC Health reported a decline in revenue for Q2 2024, with $35.02 million compared to $36.16 million in Q2 2023, indicating potential challenges in maintaining sales growth. (marketinference.com)
The company's net income decreased by 19.97% in 2024, reflecting potential profitability issues. (stockanalysis.com)
NRC Health's stock price has experienced significant volatility, with a 54.49% decline in 2024, raising concerns about investor confidence and market stability. (alphacubator.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.

NRC Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NRC

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Jul11
National Research
Dividend·Payment
$0.12Per share
FAQs